New drug combo offers hope for Hard-to-Treat transplant complication
NCT ID NCT06233110
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 30 times
Summary
This early-phase study tests a combination of two drugs, ruxolitinib and fostamatinib, for people with chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack the patient's body. The main goal is to find a safe and effective dose of fostamatinib when added to standard ruxolitinib treatment. About 30 adults who have had a stem cell transplant will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Conditions
Explore the condition pages connected to this study.